Paul J. Catalano

Also affiliated with Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, Dana-Farber Brigham Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 33 papers. Top paper: “Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)”.

Randomized Study of Temozolomide or Temozolomide and Capecitabine in Patients With Advanced Pancreatic Neuroendocrine Tumors (ECOG-ACRIN E2211)

Journal of Clinical Oncology(2022)10.1200/jco.22.01013

N/A

4.9DataRank · unranked

297 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +14 more

The GIANT trial (ECOG-ACRIN EA2186) methods paper: A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer - defining a new treatment option for older vulnerable patients

Journal of Geriatric Oncology(2023)10.1016/j.jgo.2023.101474

N/A

0.693DataRank · unranked

18 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Helga S. Marques +8 more

Combining antivascular endothelial growth factor and anti-epidermal growth factor receptor antibodies: randomized phase II study of irinotecan and cetuximab with/without ramucirumab in second-line colorectal cancer (ECOG-ACRIN E7208)

JNCI Journal of the National Cancer Institute(2024)10.1093/jnci/djae114

N/A

0.443DataRank · unranked

10 citations

Paul J. Catalano, Michelle Weitz, Edith Mitchell, Deirdre Jill Cohen, Peter J O’Dwyer +9 more

APOLLO: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2 or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.4_suppl.tps763

N/A

0.330DataRank · unranked

8 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Evaluation of predictive biomarkers for nivolumab in patients (pts) with metastatic clear cell renal cell carcinoma (mccRCC) from the CheckMate-025 (CM-025) trial.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5023

N/A

0DataRank · unranked

12 citations

Opeyemi A. Jegede, Miriam Sant’Angelo, Sonia Moreno, David A. Braun, Megan Wind‐Rotolo +15 more

Immunogenomic characterization of advanced clear cell renal cell carcinoma treated with PD-1 blockade.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.5010

N/A

0DataRank · unranked

2 citations

Yue Hou, Ziad Bakouny, Miriam Ficial, Miriam Sant’Angelo, Petra Ross‐Macdonald +15 more

Cultural Sets Shape Adult Conceptualizations and Relationships to Nature

Sustainability(2021)10.3390/su132011266

N/A

0DataRank · unranked

12 citations

José Guillermo Cedeño Laurent, Jarvis T. Chen, Paul J. Catalano, John D. Spengler, Linda Powers Tomasso

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

Journal of Clinical Oncology(2021)10.1200/jco.2021.39.15_suppl.4064

N/A

0DataRank · unranked

13 citations

Michelle Weitz, Paul J. Catalano, Michael K. Gibson, Lakshmi Rajdev, Onkar V. Khullar +15 more

Clinical validation of deep learning algorithms for radiotherapy targeting of non-small-cell lung cancer: an observational study

The Lancet Digital Health(2022)10.1016/s2589-7500(22)00129-7

N/A

0DataRank · unranked

72 citations

Danielle S. Bitterman, Christian V. Guthier, Jack M. Qian, Hannah Roberts, Subha Perni +11 more

A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: Final analysis of efficacy and evaluation of MGMT (ECOG-ACRIN E2211).

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4004

N/A

0DataRank · unranked

21 citations

Noah Graham, Paul J. Catalano, Halla Nimeiri, George A. Fisher, Teri A. Longacre +15 more

Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms (GEPNENs): ECOG-ACRIN EA2142.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.4020

N/A

0DataRank · unranked

13 citations

Paul J. Catalano, George A. Fisher, Daniel B. Rubin, Andrei Iagaru, David S. Klimstra +11 more

A randomized phase II study of gemcitabine and nab-paclitaxel compared with 5-fluorouracil, leucovorin, and liposomal irinotecan in older patients with treatment-naïve metastatic pancreatic cancer (GIANT): ECOG-ACRIN EA2186—Trials in progress.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.tps4185

N/A

0DataRank · unranked

0 citations

Paul J. Catalano, Leon Lenchik, Robert D. Boutin, Xin Yao, Shaalan Beg +9 more

Low skeletal muscle area and association with toxicity and hospitalization with chemotherapy in advanced non–small cell lung cancer.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.8532

N/A

0DataRank · unranked

0 citations

John Cijiang He, Kee‐Young Shin, Jakob Weiß, Yu‐Hui Chen, Paul J. Catalano +5 more

PD-1 Expression on Intratumoral Regulatory T Cells Is Associated with Lack of Benefit from Anti–PD-1 Therapy in Metastatic Clear-Cell Renal Cell Carcinoma Patients

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-23-2274

N/A

0DataRank · unranked

37 citations

Opeyemi A. Jegede, Sayed Matar, Nourhan El Ahmar, Destiny J. West, Emily Walton +16 more

Automated temporalis muscle quantification and growth charts for children through adulthood

Nature Communications(2023)10.1038/s41467-023-42501-1

N/A

0DataRank · unranked

17 citations

Kevin X. Liu, Anurag Saraf, Zezhong Ye, Paul J. Catalano, Viviana Benitez +18 more

In situ psycho-cognitive assessments support self-determined urban green exercise time

Urban forestry & urban greening(2023)10.1016/j.ufug.2023.128005

N/A

0DataRank · unranked

8 citations

John D. Spengler, Paul J. Catalano, Jarvis T. Chen, José Guillermo Cedeño Laurent, Linda Powers Tomasso

Multi-institutional Characterization of Outcomes for Pediatric and Young Adult Patients With High-Risk Myxopapillary Ependymoma After Radiation Therapy

International Journal of Radiation Oncology*Biology*Physics(2023)10.1016/j.ijrobp.2023.06.2293

N/A

0DataRank · unranked

3 citations

Daniel J. Indelicato, Arnold C. Paulino, Wen Shen Looi, Paul J. Catalano, Murali Chintagumpala +8 more

Treatment-free survival (TFS) outcomes from the phase II study of nivolumab and salvage nivolumab + ipilimumab in advanced clear cell renal cell carcinoma (aRCC) (HCRN GU16-260-Cohort A).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.6_suppl.604

N/A

0DataRank · unranked

5 citations

Opeyemi A. Jegede, David F. McDermott, Naomi B. Haas, Mehmet Asım Bilen, Mark N. Stein +11 more

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.tps4202

N/A

0DataRank · unranked

3 citations

Sung Chul Hong, Anup Kasi, Eileen M. O’Reilly, Shishir K. Maithel, Xin Yao +10 more

Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2023)10.1158/2326-6066.c.6550380

N/A

0DataRank · unranked

0 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Data from KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

(2023)10.1158/2326-6066.c.6550380.v1

N/A

0DataRank · unranked

0 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Novel use of alternate (Alt) response (Rp) criteria (Cr) for early prediction of outcomes in pancreatic (P) neuroendocrine tumors (NETs): Utilizing banked imaging data from the ECOG-ACRIN E2211 study.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.4133

N/A

0DataRank · unranked

0 citations

Elizabeth A. Handorf, Pamela L. Kunz, Emel Alkım, Lauren M. Burke, Paul J. Catalano +10 more

Large language models to identify social determinants of health in electronic health records

npj Digital Medicine(2024)10.1038/s41746-023-00970-0

N/A

0DataRank · unranked

264 citations

Shan Chen, Spencer A. Thomas, Tafadzwa L. Chaunzwa, Idalid Franco, Benjamin H. Kann +10 more

Plasma Kidney Injury Molecule-1 for Preoperative Prediction of Renal Cell Carcinoma Versus Benign Renal Masses, and Association With Clinical Outcomes

Journal of Clinical Oncology(2024)10.1200/jco.23.00699

N/A

0DataRank · unranked

25 citations

Valérie Gaborieau, Samuel M. Niman, Anush Mukeria, Xiaowen Liu, Krishna P. Maremanda +14 more

Stepwise Transfer Learning for Expert-level Pediatric Brain Tumor MRI Segmentation in a Limited Data Scenario

Radiology Artificial Intelligence(2024)10.1148/ryai.230254

N/A

0DataRank · unranked

21 citations

Zezhong Ye, Sanjay P. Prabhu, Michael C. Tjong, Yining Zha, Anna Zapaishchykova +13 more

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)

Journal for ImmunoTherapy of Cancer(2024)10.1136/jitc-2023-008293

N/A

0DataRank · unranked

6 citations

Opeyemi A. Jegede, Naomi B. Haas, David F. McDermott, Mehmet Asım Bilen, Mark N. Stein +11 more

Patterns of recurrence after radiotherapy for high-risk neuroblastoma: Implications for radiation dose and field

Radiotherapy and Oncology(2024)10.1016/j.radonc.2024.110384

N/A

0DataRank · unranked

4 citations

S. Shaaban, Jie Jane Chen, Rochelle Bagatell, Benjamin Lerman, Paul J. Catalano +20 more

Hypofractionated Palliative Radiotherapy for Relapsed and Refractory High-Risk Neuroblastoma

Current Oncology(2025)10.3390/curroncol32030124

N/A

0DataRank · unranked

1 citations

Karen J. Marcus, Steven G. DuBois, Paul J. Catalano, Suzanne Shusterman, Myrsini Ioakeim‐Ioannidou +6 more

KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1

Cancer Immunology Research(2020)10.1158/2326-6066.cir-20-0315

N/A

0DataRank · unranked

113 citations

Abdulla Berjis, Julie C. Konge, Kathleen M. Mahoney, Alyssa N. Klee, Samuel S. Freeman +14 more

Intergroup randomized phase III study of adjuvant FOLFIRI, FOLFOX, or 5-FU/leucovorin for stage II/III rectal cancer: ECOG-ACRIN E3201

The Oncologist(2025)10.1093/oncolo/oyaf416

N/A

0DataRank · unranked

0 citations

Fengmin Zhao, Neal J. Meropol, Bruce J. Giantonio, Robert B. Diasio, Patrick J. Flynn +14 more

Doxorubicin and subsequent risk of cardiovascular diseases among survivors of diffuse large B-cell lymphoma in Hong Kong

Blood Advances(2020)10.1182/bloodadvances.2020002737

N/A

0DataRank · unranked

17 citations

Miguel Ángel Luque-Fernández, Yu‐Hui Chen, Paul J. Catalano, Chi‐Leung Chiang, Eric Yuk Fai Wan +4 more

Arterial Spin Labeled Perfusion MRI for the Evaluation of Response to Tyrosine Kinase Inhibition Therapy in Metastatic Renal Cell Carcinoma

Radiology(2020)10.1148/radiol.2020201763

N/A

0DataRank · unranked

16 citations

Rupal S. Bhatt, Meaghan F. Strob, Opeyemi A. Jegede, Maryellen Sun, David C. Alsop +6 more

The Role of Individual and Small-Area Social and Environmental Factors on Heat Vulnerability to Mortality Within and Outside of the Home in Boston, MA

Journal of the Association for Information Systems(2020)10.3390/cli8020029

N/A

0DataRank · unranked

26 citations

Joseph G. Allen, Paul J. Catalano, John O. Spengler, Augusta Williams